New Delhi: India’s drug regulator has approved Itolizumab, a drug used to cure skin ailment psoriasis, for “restricted emergency use” to treat COVID-19 patients with moderate to severe acute respiratory distress.
Considering the unmet medical needs to treat COVID-19, Drugs Controller General of India, Dr VG Somani, approved the monoclonal antibody injection Itolizumab, on Friday, officials said.
“The approval was given after its clinical trials on COVID-19 patients in India were found satisfactory by an expert committee comprising pulmonologists, pharmacologists and medicine specialists from AIIMS, among others, for treatment of cytokine release syndrome,” PTI quoted an unnamed official as saying.
“It is already an approved drug of Biocon for treating psoriasis for last many years,” the official added.
He also informed that written informed consent of each patient is required before the use of this drug.
Kolkata: The Railway Protection Force (RPF) of Eastern Railway (ER) claimed to have seized foreign… Read More
Bhubaneswar: Newly-appointed Odisha Congress president Bhakta Charan Das underwent a successful surgery for an injury… Read More
Bhubaneswar: Thunderstorm activity with lightning, gusty surface wind and hail may continue in Odisha till… Read More
Bhadrak: Police busted a sex racket operating from a hotel in Odisha's Bhadrak district late… Read More
New Delhi: Delhi Metro Rail Corporation (DMRC) claimed to have scaled the highest point till… Read More
Bhubaneswar: The Odisha Vigilance sleuths on Sunday apprehended Assistant Agriculture Officer lock Technology Manager and… Read More
This website uses cookies.
